ICON’s Accellacare Site Network Enhances Oncology Research Through New Cancer Institute Partnership ICON plc today announced a significant expansion of oncology research capabilities within its Accellacare Site Network through the…
Will Forte Partners with Teva to Launch “Honestly HD”—A Candid Conversation About Huntington’s Disease Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced…
DARZALEX FASPRO® quadruplet approved in U.S. for transplant-ineligible newly diagnosed multiple myeloma Johnson & Johnson announced today the U.S. Food and Drug Administration (FDA) approved DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) in combination…
Neurocrine Biosciences Launches Phase 2 Trial of NBI-1065890 for Tardive Dyskinesia in Adults Neurocrine Biosciences, Inc. today announced the initiation of its Phase 2 clinical study of investigational compound NBI-1065890…
BioMarin Moves to Strengthen BalanceBioMarin Announces Proposed Private Offering of Senior Notes and New Senior Secured Term Loan Syndication BioMarin Pharmaceutical Inc. announced today that it intends to offer, subject…
WuXi Biologics and HanchorBio Forge Strategic Partnership to Advance Next-Gen Bi- and Multi-Functional Fusion Proteins WuXi Biologics, a global leading Contract Research, Development and Manufacturing Organization (CRDMO), and HanchorBio Inc.…
Bayer to Showcase New Phase III Data and Innovations in Radiology Portfolio at ECR 2026 Bayer will present advancements of its comprehensive radiology portfolio at the 2026 European Congress of…
GSK’s RSV Vaccine, Arexvy, Gains European Approval for Use in All Adults Aged 18 and Older GSK plc today announced that its adjuvanted recombinant respiratory syncytial virus (RSV) vaccine, Arexvy,…
Trelegy Ellipta Gains Approval in China for Adults with Uncontrolled Asthma GSK plc today announced that China’s National Medical Products Administration (NMPA) has approved a new indication for Trelegy Ellipta (fluticasone furoate…
Aspect Biosystems and Novo Nordisk Advance Partnership to Develop Curative Diabetes Therapies Novo Nordisk and Aspect Biosystems today announced they are entering a new phase of their partnership to develop…
Lilly’s Sacituzumab Govitecan Receives U.S. FDA Breakthrough Therapy Designation for Platinum-Resistant Ovarian Cancer Eli Lilly and Company today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation…
FDA Awards Orphan Drug Designation to BlueRock Therapeutics’ Investigational Cell Therapy OpCT-001 Bayer AG and its wholly owned, independently operated subsidiary BlueRock Therapeutics LP, a clinical stage cell therapy company,…